BioCryst Reports First Quarter 2018 Financial Results

Pharmaceutical Investing

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2018. As quoted in the press release: For the three months ended March 31, 2018, total revenues were $4.0 million, compared to $9.4 million in the first quarter of 2017. The decrease in revenue was primarily associated with infrequent revenue events that …

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2018.

As quoted in the press release:

For the three months ended March 31, 2018, total revenues were $4.0 million, compared to $9.4 million in the first quarter of 2017. The decrease in revenue was primarily associated with infrequent revenue events that occurred in 2017 that did not recur in 2018. Those 2017 events were the recognition of $4.1 million of royalty revenue from Japanese government stockpiling of RAPIACTA^® and a $2.0 million payment for the Canadian regulatory approval of RAPIVAB^®.
Research and Development (“R&D”) expenses for the first quarter of 2018 increased to $18.4 million from $16.8 million in the first quarter of 2017, primarily due to additions in R&D personnel and increased spending on our hereditary angioedema (“HAE”) and preclinical programs. These increases were partially offset by a decrease in the Company’s peramivir and galidesivir development spending in 2018.

Click here to read the full press release.

approval financial results regulatory approval Pharmaceutical Investing